Literature DB >> 16965319

Predictive testing for Huntington disease: interpretation and significance of intermediate alleles.

A Semaka1, S Creighton, S Warby, M R Hayden.   

Abstract

Direct mutation analysis for Huntington disease (HD) became possible in 1993 with the identification of an expanded CAG trinucleotide repeat as the mutation underlying the disease. Expansion of CAG length beyond 35 repeats may be associated with the clinical presentation of HD. HD has never been seen in a person with a CAG size of <36 repeats. Intermediate alleles are defined as being below the affected CAG range but have the potential to expand to >35 CAG repeats within one generation. Thus, children of intermediate allele carriers have a low risk of developing HD. Currently, the intermediate allele range for HD is between 27 and 35 CAG repeats. In this study, we review the current knowledge on intermediate alleles for HD including the CAG repeat range, the intermediate allele frequency, and the clinical implications of an intermediate allele predictive test result. The factors influencing CAG repeat expansion, including the CAG size of the intermediate allele, the sex and age of the transmitting parent, the family history, and the HD gene sequence and haplotype, will also be reviewed.

Entities:  

Mesh:

Year:  2006        PMID: 16965319     DOI: 10.1111/j.1399-0004.2006.00668.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  39 in total

1.  The right to ignore genetic status of late onset genetic disease in the genomic era; Prenatal testing for Huntington disease as a paradigm.

Authors:  A Erez; K Plunkett; V R Sutton; A L McGuire
Journal:  Am J Med Genet A       Date:  2010-07       Impact factor: 2.802

2.  Clinical utility gene card for: Huntington's disease.

Authors:  Carsten Saft; Blair R Leavitt; Jörg T Epplen
Journal:  Eur J Hum Genet       Date:  2013-10-09       Impact factor: 4.246

3.  Genetics of Huntington disease.

Authors:  S Mahalingam; L M Levy
Journal:  AJNR Am J Neuroradiol       Date:  2013-11-14       Impact factor: 3.825

Review 4.  CREB: a multifaceted regulator of neuronal plasticity and protection.

Authors:  Kensuke Sakamoto; Kate Karelina; Karl Obrietan
Journal:  J Neurochem       Date:  2010-12-02       Impact factor: 5.372

5.  CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease.

Authors:  Yun-Sik Choi; Boyoung Lee; Hee-Yeon Cho; Iza B Reyes; Xin-An Pu; Takaomi C Saido; Kari R Hoyt; Karl Obrietan
Journal:  Neurobiol Dis       Date:  2009-07-24       Impact factor: 5.996

6.  Case report: concurrent Wilson disease and Huntington disease: lightning can strike twice.

Authors:  Andrea Zanko; Liane Abrams
Journal:  J Genet Couns       Date:  2014-11-08       Impact factor: 2.537

7.  Huntington's disease: lessons from prion disorders.

Authors:  Melanie Alpaugh; Francesca Cicchetti
Journal:  J Neurol       Date:  2021-02-24       Impact factor: 4.849

8.  Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.

Authors:  Annie Killoran; Kevin M Biglan; Joseph Jankovic; Shirley Eberly; Elise Kayson; David Oakes; Anne B Young; Ira Shoulson
Journal:  Neurology       Date:  2013-04-26       Impact factor: 9.910

9.  "Grasping the grey": patient understanding and interpretation of an intermediate allele predictive test result for Huntington disease.

Authors:  A Semaka; L G Balneaves; M R Hayden
Journal:  J Genet Couns       Date:  2012-08-18       Impact factor: 2.537

Review 10.  Prospects for neuroprotective therapies in prodromal Huntington's disease.

Authors:  Abhishek Chandra; Ashu Johri; M Flint Beal
Journal:  Mov Disord       Date:  2014-02-26       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.